Drawing for RANIVIZ

USPTO serial 79247097

RANIVIZ

Reviewed by CopyMark Law Group

Status 402
Filing date
Status date
Registration date
—
Examiner
LAVACHE, LINDA M
Law office
TMEG LAW OFFICE 106

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with RANIVIZ?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
005Medicines for the treatment of age-related macular degenerationSECTION 70 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Apr 10, 2020DENANOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED—
Apr 9, 2020DETHDEATH OF INTERNATIONAL REGISTRATION—
Apr 8, 2020RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Apr 7, 2020ALIEASSIGNED TO LIE—
Feb 20, 2020ADCHCHANGE OF NAME/ADDRESS REC'D FROM IB—
Sep 11, 2019RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Mar 23, 2019RFNTREFUSAL PROCESSED BY IB—
Mar 7, 2019RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Mar 7, 2019RFRRREFUSAL PROCESSED BY MPU—
Feb 28, 2019RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Feb 27, 2019CNSLSUSPENSION LETTER WRITTEN—
Feb 22, 2019RFWRNON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW—
Feb 14, 2019RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Feb 13, 2019CNSLSUSPENSION LETTER WRITTEN—
Feb 7, 2019DOCKASSIGNED TO EXAMINER—
Dec 18, 2018MAFRAPPLICATION FILING RECEIPT MAILED—
Dec 13, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Dec 6, 2018REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance